In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Martin Schoen discussing a comparison of outcomes with docetaxel or androgen receptor pathway inhibitor combination therapy for metastatic hormone-sensitive prostate cancer (mHSPC) by volume of ...

PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated or positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with ...

Israeli pharmaceutical company RedHill Biopharma has initiated a placebo-controlled Phase II trial to assess the combination ...

RedHill Biopharma (RDHL) announced the initiation of a Phase 2 clinical study to evaluate the efficacy of its opaganib candidate in combination ...

PURPOSE: We determined the incidence of defects in 3 enzymes, namely 3beta-hydroxysteroid dehydrogenase, 17alpha-hydroxylase and 17,20-lyase, on the testosterone biosynthetic pathway in boys with ...

Testosterone is typically understood to contribute to maleness and masculinity, although it also responds to behaviors such as competition. Competi... Effects of gendered behavior on testosterone in ...

Evan Y. Yu, MD, discusses the design and objectives of the phase 3 PEACE 3 study, which evaluates the combination of enzalutamide (ENZA) and radium-223 (Ra-223) in androgen receptor pathway inhibitor ...

That's because alcohol promotes inflammation, making it difficult for testosterone-producing cells to function properly. Plus, excessive alcohol intake disrupts the activity of your ...

Androgen insensitivity is an umbrella term for a number of genetic conditions where the body does not respond appropriately to testosterone and other androgens. There are multiple causes of androgen ...

In a video interview, William K. Oh, MD, director of precision medicine at Yale Cancer Center and Smilow Cancer Hospital discusses the latest breakthroughs in advanced prostate cancer treatment.

Researchers will use a lipidomic biomarker test to select patients with a poor prognosis who may benefit from an investigational combination therapy.